Omniome, Inc.

Glenmark Pharmaceuticals S.a.

Pacific Biosciences of California, Inc.

Mark A Bernard

Eugene Tu

Kandaswamy Vijayan

Corey M Dambacher

Joseph Franklin Rokicki

Kerry Wilson

Elias Lazarides

Catherine Mary Woods

Catherine Woods

The present disclosure provides compositions, methods and systems for sequencing a template nucleic acid using a polymerase based, nucleic acid binding reaction involving examination of the interaction between a polymerase and template nucleic acid in the presence of one or more unlabeled nucleotides. The methods rely, in part, on identifying a base of a template nucleic acid during nucleic acid synthesis by controlling the sequencing reaction conditions. Template nucleic acid bases may be identified during an examination step followed by an optional incorporation step.

Nucleic acid sequencing methods and systems

Provided are compositions, methods and systems for determining the sequence of a template nucleic acid using a polymerase-based, sequencing-by-binding procedure. An examination step involves monitoring the interaction between a polymerase and template nucleic acid in the presence of one or more nucleotides. Identity of the next correct nucleotide in the sequence is determined without incorporation of any nucleotide into the structure of the primer by formation of a phosphodiester bond. An optional incorporation step can be used after the examination step to extend the primer by one or more nucleotides, thereby incrementing the template nucleotides that can be examined in a subsequent examination step. The sequencing-by-binding procedure does not require the use of labeled nucleotides or polymerases, but optionally can employ these reagents.

Method and system for sequencing nucleic acids

The invention relates to anti-&#x3b1;2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of &#x3b1;2 integrin and inhibit the interaction of &#x3b1;2&#x3b2;1 integrin with collagen. Also disclosed are therapeutic uses of anti-&#x3b1;2 integrin antibodies in treating &#x3b1;2&#x3b2;1-mediated disorders, including anti-&#x3b1;2 integrin antibodies that bind to &#x3b1;2 integrin without activating platelets.

Anti-alpha2 integrin antibodies and their uses

Anti-&#x3b1;2 integrin antibodies and their uses

Growing community of inventors

Poway, CA, United States of America

Mark A Bernard